PharmaVOICE 100 Celebration Panelists
The Third Annual
PharmaVOICE 100 Celebration
September 14, 2017
Apella Event Space
Riverpark, a Tom Colicchio Restaurant
The Alexandria Center for Life Science
450 East 29th Street New York, NY 10016
Amir Kalali M.D.
Head, Neuroscience Center of Excellence
Dr. Kalali, an inaugural PharmaVOICE Red Jacket winner, is Head, Neuroscience Center of Excellence at Quintiles. In this role, he is responsible for the enterprise-wide strategy for Neuroscience, encompassing drug development and health care services. He has been responsible for numerous successful drug development programs that have led to new treatments for patients.Recognized globally as a leader in drug development and healthcare with an emphasis on innovation, collaboration, and the intersection with new technology, Dr. Kalali was the Founding Chairman of the Executive Committee of the International Society for CNS Drug Development (ISCDD), a founding member of the International Society for CNS Clinical Trials and Methodology (ISCTM), where he serves on Executive Committee, the Scientific Committee, and previously chaired the Membership and Publication Committees. He is also a founder and Co-Chair of the Scientific Program Committee of the CNS Summit, and serves on the Scientific Program Committee of the American College of Neuropsychopharmacology. He is Professor of Psychiatry at University of California San Diego, Editor of the journal Innovations in Clinical Neuroscience, and the Lead Editor of the book Essential CNS Drug Development, published by Cambridge University Press. He has been involved in initiatives by the Institute of Medicine Forum on Drug Discovery, Development, and Translation, as well as the NIH FAST and the NIH NCATS New Therapeutic Uses program.
Multiple Myeloma Research Foundation
Multiple Myeloma Research Consortium
Kathy Giusti, a multiple myeloma patient, is the founder of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC) and currently serves on the MMRF Board of Directors. She also has more than two decades of experience in the pharmaceutical industry, previously holding senior positions at G.D. Searle and Merck. Since founding the MMRF in 1998, Ms. Giusti has led the foundation in establishing innovative, collaborative research models in the areas of tissue banking, genomics, and clinical trials. Kathy’s leadership has earned her several prestigious awards and recognitions. She was ranked No. 19 on Fortune Magazine’s Worlds’ 50 Greatest Leaders. In 2011, she was named to the TIME 100 List of the world’s most influential people. She has been named an Open Science Champion of Change by the White House and has also received the American Association for Cancer Research Centennial Medal for Distinguished Public Service, the Harvard Business School Alumni Achievement Award, and the Healthcare Businesswomen’s Association’s Woman of the Year Award.
Craig H. Lipset
Head of Clinical Innovation
Craig H. Lipset is Head of Clinical Innovation within Worldwide Research & Development at Pfizer. Craig’s team is responsible for impacting clinical research through digital tools, innovative research approaches and novel collaborations. He serves on the Board of Directors for the Foundation for Sarcoidosis Research, the Board of Directors for the MedStar Health Research Institute, the Operations Committee for TransCelerate BioPharma, and as a Mentor at health tech accelerator Blueprint Health. Craig also serves on the Editorial Board for Therapeutic Innovation & Regulatory Science. Craig previously served as Venture Partner in Pfizer Venture Investments as well as Senior Director in Molecular Medicine within Pfizer R&D. Prior to Pfizer he served as Associate Vice President of Program Management at Adnexus Therapeutics (acquired by Bristol-Myers Squibb), and on the founding management team for Perceptive Informatics (now part of PAREXEL International).
Mike Rea has worked in global pharma for 25 years, and is a recognized industry leader, and one of the top 10 innovators in pharma by PharmaPhorum. Since founding the path-to-market design practice IDEA Pharma, Mike has led strategy for more than 100 pharmaceutical brands, including more than half of the 50 fastest-growing brands in the 2005 to 2010 period, as well as three in 10 of the products named as blockbuster launches by Reuters in 2015. With practices across San Francisco, New York, Basel, and the UK, he continues to work directly with clients on path-to-market design. Mike has chaired several international pharma conferences, and is regarded as an industry expert and a provocative voice on pharmaceutical positioning, innovation, portfolio strategy, and life-cycle management.
Johnson & Johnson Innovation JLABS
As Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a biotech company. Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set out to create a better model, which now forms the basis for JLABS’ operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also initiated, raised capital and secured large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and a MBA from INSEAD in France.